JPS58172315A - 共働的消炎性薬学組成物 - Google Patents
共働的消炎性薬学組成物Info
- Publication number
- JPS58172315A JPS58172315A JP58002924A JP292483A JPS58172315A JP S58172315 A JPS58172315 A JP S58172315A JP 58002924 A JP58002924 A JP 58002924A JP 292483 A JP292483 A JP 292483A JP S58172315 A JPS58172315 A JP S58172315A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- formula
- indomethacin
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 230000002195 synergetic effect Effects 0.000 title abstract description 10
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract description 4
- 230000001741 anti-phlogistic effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002699 waste material Substances 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract description 72
- 229960000905 indomethacin Drugs 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 13
- VFMCUTPRJLZEEW-UHFFFAOYSA-N 4h-pyrido[1,2-a]pyrimidine Chemical class C1=CC=CN2CC=CN=C21 VFMCUTPRJLZEEW-UHFFFAOYSA-N 0.000 abstract description 2
- SEISMQVOJUJKGE-UHFFFAOYSA-M ethyl 1,6-dimethyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-1-ium-3-carboxylate;methyl sulfate Chemical compound COS([O-])(=O)=O.C1CCC(C)N2C(=O)C(C(=O)OCC)=C[N+](C)=C21 SEISMQVOJUJKGE-UHFFFAOYSA-M 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010036030 Polyarthritis Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- -1 fi-propyl Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001193704 Orbus Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000006490 Spondylolysis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229930187294 kinoin Natural products 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU82976A HU186607B (en) | 1982-03-31 | 1982-03-31 | Process for preparing pharmaceutical composition with synergetic antiinflammatory activity |
| HU976/82 | 1982-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58172315A true JPS58172315A (ja) | 1983-10-11 |
| JPH0314287B2 JPH0314287B2 (enExample) | 1991-02-26 |
Family
ID=10952276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58002924A Granted JPS58172315A (ja) | 1982-03-31 | 1983-01-13 | 共働的消炎性薬学組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4556563A (enExample) |
| EP (1) | EP0091179B1 (enExample) |
| JP (1) | JPS58172315A (enExample) |
| AT (1) | ATE26399T1 (enExample) |
| DD (1) | DD209576A5 (enExample) |
| DE (1) | DE3370761D1 (enExample) |
| HU (1) | HU186607B (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795769C3 (de) * | 1966-11-02 | 1978-11-02 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt, Budapest | 6,7,8,9-Tetrahydro-2H-pyrido [Ua] pyrimidinderivate, deren Salze mit Säuren und quaternäre Methosalze, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
| HU173438B (hu) * | 1975-11-27 | 1979-05-28 | Chinoin Gyogyszer Es Vegyeszet | Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom |
-
1982
- 1982-03-31 HU HU82976A patent/HU186607B/hu not_active IP Right Cessation
-
1983
- 1983-01-05 AT AT83300028T patent/ATE26399T1/de not_active IP Right Cessation
- 1983-01-05 DE DE8383300028T patent/DE3370761D1/de not_active Expired
- 1983-01-05 EP EP83300028A patent/EP0091179B1/en not_active Expired
- 1983-01-11 DD DD83247165A patent/DD209576A5/de not_active IP Right Cessation
- 1983-01-13 JP JP58002924A patent/JPS58172315A/ja active Granted
- 1983-03-10 US US06/474,750 patent/US4556563A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4556563A (en) | 1985-12-03 |
| DE3370761D1 (en) | 1987-05-14 |
| EP0091179A1 (en) | 1983-10-12 |
| JPH0314287B2 (enExample) | 1991-02-26 |
| EP0091179B1 (en) | 1987-04-08 |
| DD209576A5 (de) | 1984-05-16 |
| ATE26399T1 (de) | 1987-04-15 |
| HU186607B (en) | 1985-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6429228B1 (en) | Local anesthetic for external use | |
| CZ287558B6 (en) | Pharmaceutical preparation | |
| Qureshi et al. | Topical nonsteroidal antiinflammatory drugs versus oil of evening primrose in the treatment of mastalgia | |
| IL106743A (en) | Tablets with improved bioavailability of the active material clodronic acid | |
| BRPI0708645A2 (pt) | composições e métodos para o tratamento de artrite reumatóide | |
| JPH03291221A (ja) | 皮膚外用液剤 | |
| CN106344589B (zh) | 一种稳定性改善的卡泊三醇倍他米松组合物 | |
| US20060009426A1 (en) | Pharmaceutical compositions comprising calcitriol and a clobetasol propionate | |
| IT9019793A1 (it) | Composizioni farmaceutiche contenenti ipriflavone, procedimento per la loro preparazione e relativo impiego terapeutico | |
| JPS58172315A (ja) | 共働的消炎性薬学組成物 | |
| US10507190B2 (en) | Method for treating hyperhidrosis with dexmecamylamine | |
| BRPI0609779A2 (pt) | composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide | |
| ZA200505174B (en) | Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate | |
| JP2023164921A (ja) | 医薬組成物 | |
| JPS6064922A (ja) | 皮膚外用剤 | |
| DE2820900A1 (de) | Arzneimittel zur behandlung von gastritiden, gastroduodenitiden und gastroduodenaler ulcera | |
| US4070463A (en) | Antimotion sickness remedy | |
| Anilkumar | Formulation of ondansetron HCl matrix tablets with microenvironmental pH modifier for improved dissolution and bioavailability under hypochlorhydria | |
| CA2417677A1 (en) | Medicaments containing cilansetron for treating non-obstipated male ibs patients | |
| WO1995020394A1 (de) | Orale arzneiform enthaltend colestipol als träger mit sauren wirkstoffen und verfahren zu ihrer herstellung | |
| JPS63301817A (ja) | イブプロフェン錠 | |
| RU2138252C1 (ru) | Комбинированный препарат "тетралгин", обладающий анальгетическим и жаропонижающим действием | |
| Nahornyi et al. | Development of technology and research of gel with pentoxifylline | |
| JP7092498B2 (ja) | 尿かぶれ改善剤 | |
| JPH0445493B2 (enExample) |